Two departures shake up AZ's immuno-oncology leadership
This article was originally published in Scrip
Executive Summary
Two of AstraZeneca's immuno-oncology leaders have left the company simultaneously, though AstraZeneca has said that the timing of the departures is coincidental. Rachel Humphrey, formerly senior vice-president and head of immune-oncology, left at the end of November for personal reasons. She has been replaced by Robert Iannone, who has worked for AZ since last year as part of the global medicines team. Mr Iannone was previously executive director of clinical research, and section head in oncology at Merck Research Laboratories.